Accession Number:

ADA595679

Title:

Augmenting Trastuzumab Therapy Against Breast Cancer Through Selective Activation of NK Cells

Descriptive Note:

Annual summary 30 Sep 2012-29 Sep 2013

Corporate Author:

STANFORD UNIV CA

Personal Author(s):

Report Date:

2013-10-01

Pagination or Media Count:

26.0

Abstract:

Trastuzumab, a monoclonal antibody mAb targeting HER-2neu, kills tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity ADCC. Strategies that enhance the activity of ADCC effectors, including natural killer NK cells, may improve trastuzumab s efficacy. NK cells that encounter trastuzumab-coated, HER2-overexpressing breast cancer cells become activated and express CD137, a costimulatory receptor. CD137 activation, which is dependent on the Fc RIII receptor, occurred both in vitro and in the peripheral blood of women with HER2- expressing breast cancer following trastuzumab treatment. Stimulation of trastuzumab-activated NK cells with an agonistic mAb against CD137 killed breast cancer cells more efficiently in vitro and in multiple HER2 in vivo models.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE